Designing Tomorrow´s Vaccines

SVF Vaccines develops innovative vaccines and immunotherapies for serious infectious diseases, based on innovations originated from research at Karolinska Institutet in Stockholm. Our lead program, SVF-001, is a therapeutic vaccine candidate for chronic hepatitis D and B infections, currently being advanced toward Phase 1 clinical development.

Our technology is designed to stimulate both antibody and T-cell responses. Its potential has been demonstrated in a completed Phase 1 clinical study of our COVID-19 vaccine candidate, SVF-002, conducted through the OpenCorona consortium. The technology is also being explored for other infectious diseases, including Crimean-Congo hemorrhagic fever.

Alongside our proprietary pipeline, SVF Vaccines collaborates with academic and industry partners, including Touchlight and Orexo, to advance vaccine development and explore new applications of our technology.